0000950123-20-008777.txt : 20200814
0000950123-20-008777.hdr.sgml : 20200814
20200814080514
ACCESSION NUMBER: 0000950123-20-008777
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200630
FILED AS OF DATE: 20200814
DATE AS OF CHANGE: 20200814
EFFECTIVENESS DATE: 20200814
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC
CENTRAL INDEX KEY: 0001703031
IRS NUMBER: 813996001
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-18477
FILM NUMBER: 201101435
BUSINESS ADDRESS:
STREET 1: 200 CLARENDON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 6175162878
MAIL ADDRESS:
STREET 1: 200 CLARENDON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
13F-HR
1
primary_doc.xml
13F-HR
LIVE
0001703031
XXXXXXXX
06-30-2020
06-30-2020
false
Bain Capital Life Sciences Investors, LLC
200 Clarendon Street
Boston
MA
02116
13F HOLDINGS REPORT
028-18477
Y
Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P. and (ii) the general partner of BC SW, LP.
The shares of common stock of Dynavax Technologies Corporation ("DVAX") included on the Information Table are as reported on Amendment No. 2 to the Schedule 13D filed by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP on May 28, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of DVAX common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding DVAX common stock following such exercise or conversion. As of June 30, 2020, such persons held an aggregate of 8,525,000 shares of DVAX common stock.
The shares of common stock of Savara Inc ("SVRA") included on the Information Table are as reported on the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 30, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise or conversion. As of June 30, 2020, such persons held an aggregate of 4,571,139 shares of SVRA common stock.
The shares of common stock of X4 Pharmaceuticals, Inc. ("XFOR") included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 9, 2019 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of XFOR common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding XFOR common stock following such exercise or conversion. As of June 30, 2020, such persons held an aggregate of 1,250,000 shares of XFOR common stock.
Adam Koppel
Managing Dir. of Bain Capital Life Sciences Investors, LLC
617-516-2000
/s/ Adam Koppel
Boston
MA
08-14-2020
3
15
954774
false
1
28-18476
Bain Capital Life Sciences Partners, LP
2
28-18478
Bain Capital Life Sciences Fund, LP
3
28-20270
BC SW, LP
INFORMATION TABLE
2
773.xml
INFORMATION TABLE FOR FORM 13F
DICERNA PHARMACEUTICALS INC
COM
253031108
103638
4080237
SH
SOLE
4080237
0
0
MARINUS PHARMACEUTICALS INC
COM
56854Q101
14540
5724235
SH
SOLE
5724235
0
0
REPLIMUNE GROUP INC
COM
76029N106
53741
2162598
SH
SOLE
2162598
0
0
SOLID BIOSCIENCES INC
COM
83422E105
11343
3871164
SH
SOLE
3871164
0
0
APTINYX INC
COM
03836N103
23179
5558425
SH
SOLE
5558425
0
0
SPRINGWORKS THERAPEUTICS INC
COM
85205L107
305815
7281307
SH
SOLE
7281307
0
0
DYNAVAX TECHNOLOGIES CORP.
COM
268158201
96646
10895773
SH
SOLE
10895773
0
0
CONSTELLATION PHARMACEUTICALS INC.
COM
210373106
42070
1400000
SH
SOLE
1400000
0
0
X4 PHARMACEUTICALS INC
COM
98420X103
15364
1648485
SH
SOLE
1648485
0
0
SAVARA INC
COM
805111101
22976
5128593
SH
SOLE
5128593
0
0
ARCUTIS BIOTHERAPEUTICS, INC.
COM
03969K108
120334
3979292
SH
SOLE
3979292
0
0
MERSANA THERAPEUTICS, INC.
COM
59045L106
80629
3445667
SH
SOLE
3445667
0
0
CRINETICS PHARMACEUTICALS, INC.
COM
22663K107
18771
1071428
SH
SOLE
1071428
0
0
SAGE THERAPEUTICS, INC.
COM
78667J108
20753
499100
SH
SOLE
499100
0
0
AEGLEA BIOTHERAPEUTICS, INC.
COM
00773J103
24975
2700000
SH
SOLE
2700000
0
0